Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver. NYSE : PFEPfizerToday's Change( -3.40 %) $ -0.90Current Price$ 25.53Key Data PointsMarket Cap$150BDay's Range$ 24.92 - $ 26.5052wk Range$ 20.91 - $ 27.69Volume112MAvg Vol68MGross Margin69.12 %Dividend Yield6.51 %Pfizer (PFE 3.40%), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 ...

And right now we are 2 minutes away from the end of the trading day. Romaine Bostick alongside Katie Greifeld, taking you through to that closing bell with the global simulcast. Carol Massar Tim Stenovec.They join us from the radio room as we welcome all of our audiences across all of our platforms, including our partnership with YouTube. An interesting day in the market. But Carol, I do want to start with that breaking news that we got a little while ago.Just a few minutes ago here, Warner Brothers Discove ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Smith is expected to start the role on Wednesday and would also serve as a board member, the government-backed mortgage provider said. ...

Pfizer has set its FY2026 profit forecast below analyst estimates, blaming projected losses on waning Covid vaccine sales and the looming patent cliff faced by some of its best-selling assets. Through this adjustment, Pfizer now expects profits ranging between $2.80 and $3 per share in 2026, which sits below the analyst estimate of $3.05 per share, as per the London Stock Exchange (LSEG). This means the company now expects its FY2026 revenue to fall somewhere between $59.5bn and $62.5bn. This compares w ...

Financial Guidance - Pfizer projects 2026 sales between $595 billion and $625 billion, roughly in line with street expectations but flat compared to the expected $62 billion for 2025 [2] - The company's profit guidance came in slightly below street expectations, at $280 to $300 per share [2] Revenue Challenges - Pfizer anticipates a $15 billion decrease in revenue from COVID products in 2026 compared to 2025 [3] - An additional $15 billion revenue hit is expected from upcoming patent expirations of older drugs [3] Mitigation Strategies - Analysts suggest the guidance reflects costs tied to recent acquisitions, including the obesity biotech Mitsera [4] - Pfizer is targeting more than $7 billion in cost savings by 2027 to partially offset revenue declines [4] Market Perception - The market did not appreciate Pfizer's 2026 guidance [1] - COVID weakness and deal dilution are still impacting Pfizer's performance [5]

Fizer falling after announcing its 2026 guidance. Our Anakica Kim Constantino has some details as the market didn't appreciate much what we got for the new year. Anakah, >> that's right, Carl.So, Fiser today issuing a modest 2026 guidance saying it expects sales to come in between 59.5% billion to 62.5% billion. And that's roughly in line with the street, but largely flat compared to the 62 billion in sales that expects for 2025. And in terms of its profit guidance, it came in slightly below what the street ...

Pfizer issued its 2026 guidance, expecting its adjusted earnings per share to come in below this year’s figures, and revised its 2025 revenue outlook https://t.co/pmHnDNPVYo ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...